Dr. Randy Longman, director of the Jill Roberts Center for Inflammatory Bowel Disease and an associate professor of medicine at Weill Cornell Medicine, and colleagues have received the NIH Director’s Transformative Research Award to develop the tools needed to understand how the gut microbiome drives metabolic pathways.
Microbes in the mammalian gut can significantly change their hosts’ amino acid and glucose metabolism, acting almost like an extra liver, according to a new preclinical study by Weill Cornell Medicine investigators.
A type of dietary fiber called inulin, commonly used in health supplements and known to have certain anti-inflammatory properties, can also promote an allergy-related type of inflammation in the lung and gut, and other parts of the body.
Scientists at the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine have developed a pipeline that enables genetic manipulation of nonmodel gut bacteria.
